LIFE:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund Hedged Units (CAD)

ETF | Sector Equity |

Last Closing

CAD 21.89

Change

-0.09 (-0.41)%

Market Cap

CAD 0.21B

Volume

8.78K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

-0.70 (-1.74%)

CAD 2.88B
ZWU:CA BMO Covered Call Utilities ETF

+0.02 (+0.18%)

CAD 1.94B
XHC:CA iShares Global Healthcare (CAD..

-0.17 (-0.23%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

-0.93 (-1.60%)

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

-0.42 (-1.94%)

CAD 0.65B
HTA:CA Harvest Tech Achievers Growth ..

-0.31 (-1.66%)

CAD 0.63B
ZUT:CA BMO Equal Weight Utilities Ind..

+0.07 (+0.31%)

CAD 0.45B
CWW:CA iShares Global Water Common Cl..

-0.20 (-0.33%)

CAD 0.34B
XUT:CA iShares S&P/TSX Capped Utiliti..

+0.01 (+0.03%)

CAD 0.32B
COW:CA iShares Global Agriculture Com..

+0.15 (+0.24%)

CAD 0.28B

ETFs Containing LIFE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.29% 26% F 35% F
Dividend Return 1.54% 58% F 39% F
Total Return 6.83% 26% F 34% F
Trailing 12 Months  
Capital Gain 8.21% 17% F 28% F
Dividend Return 1.58% 54% F 32% F
Total Return 9.79% 11% F 28% F
Trailing 5 Years  
Capital Gain 13.83% 20% F 46% F
Dividend Return 6.58% 44% F 22% F
Total Return 20.41% 17% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 0.96% N/A N/A 40% F
Dividend Return 2.08% N/A N/A 39% F
Total Return 1.13% N/A N/A 39% F
Risk Return Profile  
Volatility (Standard Deviation) 6.94% N/A N/A 57% F
Risk Adjusted Return 30.04% N/A N/A 49% F
Market Capitalization 0.21B 62% D 47% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.